-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S
When you see that almost half of the companies in the Biotechs industry in China have price-to-sales ratios (or "P/S") below 8.4x, Gan & Lee Pharmaceuticals. (SHSE:603087) looks to be giving off strong sell signals with its 13.1x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly elevated P/S.
Check out our latest analysis for Gan & Lee Pharmaceuticals
What Does Gan & Lee Pharmaceuticals' P/S Mean For Shareholders?
With revenue growth that's inferior to most other companies of late, Gan & Lee Pharmaceuticals has been relatively sluggish. One possibility is that the P/S ratio is high because investors think this lacklustre revenue performance will improve markedly. However, if this isn't the case, investors might get caught out paying too much for the stock.
Want the full picture on analyst estimates for the company? Then our free report on Gan & Lee Pharmaceuticals will help you uncover what's on the horizon.How Is Gan & Lee Pharmaceuticals' Revenue Growth Trending?
In order to justify its P/S ratio, Gan & Lee Pharmaceuticals would need to produce outstanding growth that's well in excess of the industry.
If we review the last year of revenue, the company posted a result that saw barely any deviation from a year ago. The lack of growth did nothing to help the company's aggregate three-year performance, which is an unsavory 26% drop in revenue. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.
Turning to the outlook, the next year should generate growth of 28% as estimated by the only analyst watching the company. That's shaping up to be materially lower than the 908% growth forecast for the broader industry.
With this in consideration, we believe it doesn't make sense that Gan & Lee Pharmaceuticals' P/S is outpacing its industry peers. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.
The Key Takeaway
While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.
Despite analysts forecasting some poorer-than-industry revenue growth figures for Gan & Lee Pharmaceuticals, this doesn't appear to be impacting the P/S in the slightest. Right now we aren't comfortable with the high P/S as the predicted future revenues aren't likely to support such positive sentiment for long. At these price levels, investors should remain cautious, particularly if things don't improve.
And what about other risks? Every company has them, and we've spotted 3 warning signs for Gan & Lee Pharmaceuticals (of which 2 make us uncomfortable!) you should know about.
It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
当你看到中国生物技术行业将近一半的公司的市销比(或 “P/S”)低于8.4倍时,Gan & Lee Pharmicals。(上海证券交易所股票代码:603087)的市盈率为13.1倍,似乎正在发出强劲的卖出信号。尽管如此,我们需要更深入地挖掘,以确定市盈率大幅上升是否有合理的基础。
查看我们对 Gan & Lee Pharmicals 的最新分析
甘李制药的市盈率对股东意味着什么?
由于最近的收入增长不及大多数其他公司,Gan & Lee Pharmicals一直相对疲软。一种可能性是市盈率很高,因为投资者认为这种乏善可陈的收入表现将显著改善。但是,如果不是这样,投资者可能会陷入为股票支付过多费用的困境。
想全面了解分析师对公司的估计吗?然后,我们关于Gan & Lee制药的免费报告将帮助您发现即将发生的事情。Gan & Lee Pharmicals的收入增长趋势如何?
为了证明其市盈率是合理的,Gan & Lee Pharmicals需要实现远远超过该行业的出色增长。
如果我们回顾一下去年的收入,该公司公布的业绩与去年同期几乎没有任何偏差。增长的缺乏对该公司的三年总体业绩没有任何帮助,收入下降了26%,令人失望。因此,可以公平地说,最近的收入增长对公司来说是不可取的。
谈到前景,根据唯一关注该公司的分析师的估计,明年将实现28%的增长。这将大大低于整个行业908%的增长预期。
考虑到这一点,我们认为Gan & Lee Pharmicals的市盈率超过业内同行是没有道理的。看来大多数投资者都希望公司的业务前景出现转机,但分析师对这种情况会发生的信心不大。如果市盈率降至更符合增长前景的水平,这些股东很有可能为未来的失望做好准备。
关键要点
尽管市售比率不应该成为决定你是否买入股票的决定性因素,但它是衡量收入预期的有力晴雨表。
尽管分析师预测Gan & Lee Pharmicals的收入增长数据将低于行业,但这似乎丝毫没有影响市盈率。目前,我们对高市盈率不满意,因为预期的未来收入不太可能长期支撑这种积极情绪。在这些价格水平下,投资者应保持谨慎,尤其是在情况没有改善的情况下。
那其他风险呢?每家公司都有它们,我们发现了 Gan & Lee Pharmicals 的 3 个警告信号(其中 2 个让我们感到不舒服!)你应该知道。
重要的是要确保你寻找一家优秀的公司,而不仅仅是你遇到的第一个想法。因此,如果盈利能力的增长与你对一家优秀公司的想法一致,那就来看看这份免费名单吧,列出了最近收益增长强劲(市盈率低)的有趣公司。
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧